XETR
GXI
Market cap1.15bUSD
Jul 10, Last price
28.48EUR
1D
-2.06%
1Q
66.84%
Jan 2017
-59.67%
IPO
-25.83%
Name
Gerresheimer AG
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Gerresheimer AG, alongside its global subsidiaries, stands as a prominent manufacturer of packaging solutions and drug delivery devices. The company's operations are segmented into three primary divisions. The Plastics & Devices division supplies a comprehensive range of drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic tools, serving the pharmaceutical, biotechnology, diagnostics, and medical technology sectors. This segment also produces various plastic containers and closures, such as PET bottles, eye droppers, nasal sprays, nebulizers, and applicators, suitable for solid, liquid, and ophthalmic preparations, in addition to bottles for nutritional supplements. Its Primary Packaging Glass division specializes in essential glass packaging for both pharmaceutical and cosmetic industries. Offerings include infusion, dropper, and syrup bottles, injection vials, ampoules, and cartridges. This division also provides miniature bottles and glass containers for liquid food, spices, and spirits, as well as sophisticated packaging for fragrances, deodorants, skincare, wellness items, and diverse beauty and pharmaceutical products. The Advanced Technologies division is dedicated to pioneering smart drug delivery systems. A notable innovation is its micro-pumps, which empower patients to self-administer medications for conditions like Parkinson's disease or heart failure, catering to pharmaceutical and biotech clients. Established in 1864, the company's corporate headquarters are located in Düsseldorf, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑11 | 2024‑11 | 2023‑11 | 2022‑11 | 2021‑11 | 2020‑11 | 2019‑11 | 2018‑11 | 2017‑11 | 2016‑11 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||